Seagen teams up with pro­tein degra­da­tion spe­cial­ist to make a new kind of an­ti­body con­ju­gate, pay­ing $60M up­front

Seagen, whose suite of an­ti­body-drug con­ju­gates en­ticed Pfiz­er to a $43 bil­lion buy­out, is look­ing to put a twist on the idea.

The Seat­tle-based drug­mak­er will team up with Nurix to de­vel­op de­grad­er-an­ti­body con­ju­gates (DAC), in a bid to com­bine their ex­per­tise in AD­Cs and pro­tein degra­da­tion. Seagen is hand­ing over $60 mil­lion up­front to start the deal, which can al­so de­liv­er $3.4 bil­lion in mile­stones to Nurix, on top of fu­ture roy­al­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER